Journals / Bakırköy Tıp Dergisi / 2012 / Cilt: 8 - Sayı: 2

Hodgkin lenfoma tanılı hastalarda sekonder solid kanserler

Secondary solid cancers in patients of Hodgkin's lymphoma

Pages
66–69
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Secondary tumor development, which is one of the complications in such patients, should be carefully monitored.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In this article, we will discuss secondary solid cancers identified in patients diagnosed with Hodgkin’s lymphoma (HL), with the 1996-2008 data of Antalya Cancer Recording Center which gathers population-based data in accordance with the cancer recording standards of World Health Organization’s International Cancer Research Agency.
📊
Key Findings & Data:Material and Methods: The study included patients that were histopathologically diagnosed with HL from 1996 to 2008.
💡
Conclusion & Impact:Secondary tumor development, which is one of the complications in such patients, should be carefully monitored.
🔬Design:Research Article
📍Scope:2008 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: In this article, we will discuss secondary solid cancers identified in patients diagnosed with Hodgkin’s lymphoma (HL), with the 1996-2008 data of Antalya Cancer Recording Center which gathers population-based data in accordance with the cancer recording standards of World Health Organization’s International Cancer Research Agency. Material and Methods: The study included patients that were histopathologically diagnosed with HL from 1996 to 2008. The patients without histopathological diagnosis were not included in the assessment. Results: The study covered 320 patients, including 188 (58.8%) males and 132 (41.3%) females. Nine out of 320 patients (2.8%) had developed secondary solid tumors. The most commonly identified tumors were seen in nasopharynx (2 cases) and larynx (1 case), followed by lung and breast with 2 cases for each. Conclusion: Although HL can be cured, treatment-related complications prevail. Secondary tumor development, which is one of the complications in such patients, should be carefully monitored.

Özet

Amaç: Bu yazımızda Dünya Sağlık Örgütü Uluslararası Kanser Araştırma Ajansı kanser kayıtçılığı standartlarına göre veri toplayan nüfus tabanlı Antalya Kanser Kayıt Merkezinin 1996-2008 verileri eşliğinde Hodgkin lenfoma (HL) tanılı hastalarda tespit edilen sekonder solid kanserler tartışılacaktır. Gereç ve Yöntem: Çalışmaya 1996-2008 yılları arasında histopatolojik olarak HL tanısı konulan hastalar alınmıştır. Histopatolojik tanısı olmayan hastalar değerlendirilmeye alınmamıştır. Bulgular: Çalışmaya 188’i (%58.8) erkek, 132’si (%41.3) kadın olmak üzere toplam 320 hasta alındı. Çalışmaya alınan hastaların 9’unda (%2.8) sekonder solid tümör saptandı. En sık saptadığımız solid tümörler nazofarenks (2 hasta), larenks (1 hasta) kanserleri ile ikişer hasta ile akciğer ve meme kanseri idi. Sonuç: HL kür edebilen bir hastalık olmasına rağmen tedaviye bağlı komplikasyonlar önemli orandadır. Bu hastalardaki komplikasyonlardan biri olan sekonder solid tümör gelişimi açısından dikkatli takip edilmesi gerektiğini düşünüyoruz.

🔖

Cite This Article

YILDIRIM, M., YILDIZ, M., KURTOĞLU, E., KARAKILINÇ, H., GÖKTAŞ, S., UYSAL, M., ÇELİK, B. (2012). Hodgkin lenfoma tanılı hastalarda sekonder solid kanserler. Bakırköy Tıp Dergisi, Cilt: 8 - Sayı: 2, 66–69. https://ajindex.com/articles/129374

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249
  2. Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116: 3724-3734
  3. Tarbell NJ, Thompson L, Mauch P. Thoracic irradiation in Hodgkin’s disease: disease control and long-term complications. Int J Radiat Oncol Biol Phys 1990; 18: 275-281
  4. Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006; 107: 2912-2919
  5. Kulkarni SS, Sastry PS, Saikia TK, Parikh PM, Gopal R, Advani SH. Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol 1997; 20: 354-357
  6. Sieniawski M, Reineke T, Nogova L, et al. Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group [GHSG]. Blood 2008; 111: 71-76
  7. Ng AK, Mauch PM. Late effects of Hodgkin’s disease and its treatment. Cancer J 2009; 15: 164-168
  8. Valagussa P. Second neoplasms following treatment of Hodgkin’s disease. Curr Opin Oncol 1993; 5: 805-811
  9. Behringer K, Josting A, Schiller P, et al. Solid tumors in patients treated for Hodgkin’s disease: a report from the German Hodgkin Lymphoma Study Group. Ann Oncol 2004; 15: 1079-1085
  10. Birdwell SH, Hancock SL, Varghese A, Cox RS, Hoppe RT. Gastrointestinal cancer after treatment of Hodgkin’s disease. Int J Radiat Oncol Biol Phys 1997; 37: 67-73. 11. van Leeuwen FE, Somers R, Taal BG, van Heerde P, et al. Increased risk of lung cancer, non-Hodgkin’s lymphoma, and leukemia following Hodgkin’s disease. J Clin Oncol 1989; 7: 1046-1058
  11. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin’s disease. New Engl J Med 1990; 322: 7-13. 13. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 1995; 87: 1530-1537
  12. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin’s disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001; 19: 1610-1618
  13. Sont JK, van Stiphout WA, Noordijk EM, Molenaar J, Zwetsloot- Schonk JH, Willemze R. Increased risk of second cancers in managing Hodgkin’s disease: the 20-year Leiden experience Ann Hematol 1992; 65: 213-218
  14. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second